API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Insmed intends to use the proceeds to fund continued research and development of INS1007 (brensocatib) as well as pre-commercial and, if approved, commercialization activities related to brensocatib.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INS1007
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 30, 2024
Details:
The net proceeds will fund continued research and development of INS1007 (brensocatib), a small molecule, oral, reversible inhibitor of DPP1, for non-cystic fibrosis bronchiectasis.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INS1007
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2024
Details:
INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INS1007
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2024
Details:
INS1007 (brensocatib) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INS1007
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2023
Details:
FDA has granted breakthrough therapy designation to brensocatib for treating patients with NCFBE, recognizing the strength of data from Company's Phase 2 WILLOW study and the potential for brensocatib to offer a novel, first-in-class treatment approach to bronchiectasis.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
New data from the Phase 2 WILLOW study of brensocatib (formerly known as INS1007) in non-cystic fibrosis bronchiectasis (NCFBE) will be presented during a virtual clinical trials session hosted by the American Thoracic Society (ATS).
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
Insmed will provide funding and clinical drug supply for the STOP-COVID19 trial led by the University of Dundee.
Lead Product(s): Brensocatib
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: N/AProduct Type: Small molecule
Partner/Sponsor/Collaborator: Insmed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 24, 2020
Details:
Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Placebo.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2020